Survival Outcomes of Gynecologic Oncology Patients at Assiut University

Survival Outcomes of Gynecological Oncology Patients at Assiut University: A Retrospective Study (2022-2025)

This retrospective cohort study investigates survival outcomes of gynecological oncology patients treated at Assiut University Hospital between 2022 and 2025, comparing them to international benchmarks and assessing factors affecting survival.

The study aims to evaluate overall survival (OS) and progression-free survival (PFS) of patients diagnosed with gynecological cancers (including ovarian, cervical, endometrial, vulvar, and vaginal cancers) and treated at Assiut University Hospital from January 1, 2022, to December 31, 2025. Using retrospective medical records and pathology reports, the study will analyze demographic, clinical, and treatment-related variables to identify factors influencing survival outcomes. Assiut University is a tertiary care center in a low-resource setting; thus, the study will also assess adherence to international oncology guidelines (e.g., ESMO, ASCO) and compare local survival rates with international standards. Statistical methods include Kaplan-Meier survival analysis and Cox proportional hazards modeling.

Inclusion Criteria:

- Patients diagnosed with gynecological cancers (ovarian, cervical, endometrial, vulvar, vaginal)

Patients treated at Assiut University Gynecological Oncology Department between January 1, 2022, and December 31, 2025

All age groups included

Exclusion Criteria:

- Patients with non-gynecological malignancies or metastatic cancers originating outside the gynecological tract

Patients with incomplete medical records (e.g., missing pathology reports or treatment details)

Patients with significant comorbidities independently affecting survival (e.g., advanced heart failure, severe liver or renal disease, terminal illnesses unrelated to cancer)